March 24, 2015 by Brad Perriello
Osprey Medical said it raised about $11 million (A$14 million) in a private placement for its Avert device, which is designed to prevent contrast-induced nephropathy in patients with chronic kidney disease.
Minneapolis- and Melbourne-based Osprey said the oversubscribed, 10.8-million-share round included backing from “international and domestic institutions and accredited and sophisticated investors,” including its 2 largest shareholders, Brandon Managed Funds and Talu Venture (formally CM Capital). Read more
March 23, 2015 by Brad Perriello
OrthoSensor said today that it closed out a $19 million Series C round it plans to use to commercialize its Verasense knee implant technology.
Dania Beach, Fla.-based OrthoSensor said Bridger Healthcare and the Tullis Growth Fund participated in the round. Read more
March 25, 2015 by Brad Perriello
Medtronic is among a cadre of investors backing a $44 million Series A round for Semma Therapeutics, a startup developing a cell therapy-device treatment for Type 1 diabetes.
MPM Capital led the round for Cambridge, Mass.-based Semma. Fidelity Biosciences and Arch Venture Partners also participated. Read more
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!